CeleCor Therapeutics
CeleCor Therapeutics develops novel small molecule inhibitors for immediate heart attack treatment, reducing mortality.
Founded
2017CeleCor Therapeutics develops novel small molecule inhibitors for immediate heart attack treatment, reducing mortality.
CeleCor Therapeutics, founded with a mission to revolutionize heart attack treatment, focuses on developing novel small molecule inhibitors. Their flagship product, RUC-4, is designed as a first-response treatment for segment elevated myocardial infarction (STEMI). This innovative thrombolytic agent can be administered subcutaneously via an auto-injector, aiming to reduce mortality and prevent subsequent heart failure. CeleCor targets the acute cardiovascular care market, emphasizing rapid intervention to save lives.
Key figures affiliated with CeleCor Therapeutics include leading cardiologists and pharmaceutical experts who have contributed to its groundbreaking research and development. The company has attracted significant investment from venture capital firms specializing in biotech innovations. Among its notable achievements, CeleCor has successfully advanced RUC-4 through critical stages of clinical development, demonstrating its potential to transform emergency cardiac care. The impact of CeleCor's work promises to significantly improve survival rates and outcomes for heart attack patients worldwide.
Companies similar to CeleCor Therapeutics include XyloCor Therapeutics, Thrombolytic Science, Rivus Pharmaceuticals and Elastrin Therapeutics.
CeleCor Therapeutics was founded in 2017.
CeleCor Therapeutics' headquarters is located in Del Mar, CA, US.
CeleCor Therapeutics' most recent funding round was for $17.8M (USD) in March 2022.
As of Mar 8, 2022, CeleCor Therapeutics has disclosed funding of $18.8M (USD). Undisclosed round amounts are excluded.
CeleCor Therapeutics has 6 employees as of Feb 5, 2024.
Elastrin Therapeutics
elastrin.com
